Table 1 RRP Cases reported
No | Author | Year | Country | Sex | Age | Malignancy | ICI | Onset time from RT |
|---|---|---|---|---|---|---|---|---|
1 | Current paper | 2021 | China | Male | 69 | NSCLC | Pembrolizumab | 18 months |
2 | Riviere [24] | 2021 | United States | Male | 64 | NSCLC | Nivolumab | 4.5 years |
Male | 67 | Bladder | Ipilimumab-Pembrolizumab | 6 months | ||||
Male | 52 | SCLC | Nivolumab-Ipililumab | 7 months | ||||
3 | De Giglio [25] | 2021 | Italy | Male | 53 | RCC | Nivolumab | 10 months |
4 | Itamura [26] | 2020 | Japan | NR | NR | NSCLC | Pembrolizumab | 7 months |
5 | Chen [27] | 2020 | China | Male | 64 | NSCLC | Camrelizumab | 2 years |
6 | Deutsch [23] | 2020 | France | NR | NR | NSCLC | Nivolumab | NR |
7 | Wang [28] | 2020 | China | Male | 52 | SCLC | Pembrolizumab | 6 months |
8 | McGovern [29] | 2019 | United States | Male | 82 | NSCLC | Pembrolizumab | 14 months |
9 | Nakamura [30] | 2019 | Japan | Female | 69 | RCC | Nivolumab | 9 months |
10 | Shibaki [16] | 2017 | Japan | Male | 68 | NSCLC | Nivolumab | 2 years |
Male | 55 | NSCLC | Nivolumab | 6 months |